TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors
Atezolizumab led to moderate antitumor activity in various TMB-high solid tumors. Safety was consistent with previous reports.
Authors
- Uwe M. Martens (ORCID: https://orcid.org/0000-0001-7999-4359)
- Robert N. Schuck (ORCID: https://orcid.org/0000-0002-5855-1361)
- Felice Wu
- Timothy R. Wilson (ORCID: https://orcid.org/0000-0003-0530-4663)
- Sid Patel
- David M. Thomas (ORCID: https://orcid.org/0000-0002-2527-5428)
- Maciej Jerzy Krzakowski (ORCID: https://orcid.org/0000-0003-3324-0900)
- Maria Sbirnac
- Gennaro Daniele
- Fabrice Barlesi
- Rafal Dziadziuszko
- Jae Ho Jeong
- Shirish M. Gadgeel
- Monika Kaul
- Jeong Eun. Kim
Institutions
- Amgen (United States) (US)
- Henry Ford Health System (US)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Agostino Gemelli University Polyclinic (IT)
- UNSW Sydney (AU)
- University of Ulsan (KR)
- Roche (Canada) (CA)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- SLK-Kliniken Heilbronn (DE)
- Bicêtre Hospital (FR)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3336
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche
- Foundation Medicine